The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients

We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloc, Malgorzata, Ghobrial, Rafik M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392845/
https://www.ncbi.nlm.nih.gov/pubmed/32763844
http://dx.doi.org/10.1016/j.msard.2020.102437
Descripción
Sumario:We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.

Ejemplares similares